Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Consolidated Net Income: 2015-2024

Historic Consolidated Net Income for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$486.5 million.

  • Intellia Therapeutics' Consolidated Net Income rose 21.02% to -$104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.4 million, marking a year-over-year increase of 8.75%. This contributed to the annual value of -$486.5 million for FY2024, which is 4.51% down from last year.
  • Per Intellia Therapeutics' latest filing, its Consolidated Net Income stood at -$486.5 million for FY2024, which was down 4.51% from -$465.5 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Consolidated Net Income high stood at -$134.2 million for FY2020, and its period low was -$486.5 million during FY2024.
  • Its 3-year average for Consolidated Net Income is -$467.2 million, with a median of -$465.5 million in 2023.
  • Data for Intellia Therapeutics' Consolidated Net Income shows a maximum YoY slumped of 98.59% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Consolidated Net Income stood at -$134.2 million in 2020, then plummeted by 98.59% to -$266.6 million in 2021, then crashed by 68.67% to -$449.6 million in 2022, then dropped by 3.52% to -$465.5 million in 2023, then fell by 4.51% to -$486.5 million in 2024.